Spago Nanomedical AB (publ)
STO: SPAGO.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mats Hansen
- Employees
- 13
- Headquarters
- Lund, Sweden
- IPO year
- 2013
- Market cap
- SEK 44.0M
- Website
- https://spagonanomedical.se
Loading SPAGO…
Loading profile data…Frequently asked questions about SPAGO
What does Spago Nanomedical AB (publ) (SPAGO.ST) do?
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cance...
Where does SPAGO.ST trade?
Spago Nanomedical AB (publ) (SPAGO.ST) trades on the Stockholm Stock Exchange.
What sector is SPAGO.ST in?
Spago Nanomedical AB (publ) (SPAGO.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Spago Nanomedical AB (publ)?
Mats Hansen is the chief executive officer of Spago Nanomedical AB (publ) (SPAGO.ST).
Where is Spago Nanomedical AB (publ) headquartered?
Spago Nanomedical AB (publ) is headquartered in Sweden.
Does SPAGO.ST pay a dividend?
Spago Nanomedical AB (publ) (SPAGO.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SPAGO.ST go public?
Spago Nanomedical AB (publ) (SPAGO.ST) completed its initial public offering in 2013.